<i>MET</i> Exon 14 Skipping-positive Lung Cancer That Maintained a Complete Response After Pembrolizumab Discontinuation: a Case Report

Authors

Institutions

Publication Details

Journal
Haigan
Published
2025-12-20
DOI
https://doi.org/10.2482/haigan.65.1027
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MET Exon 14 Skipping-positive Lung Cancer That Maintained a Complete Response After Pembrolizumab Discontinuation: a Case Report

Koichi Saruwatari, Shinji Iyama, Takuro Sakagami, Yuka Sakaki-Maeda et al.
Haigan
Lung Cancer Treatments and Mutations
article

MET Exon 14 Skipping-positive Lung Cancer That Maintained a Complete Response After Pembrolizumab Discontinuation: a Case Report

Koichi Saruwatari, Shinji Iyama, Takuro Sakagami, Yuka Sakaki-Maeda, Shinya Sakata, Yusuke Tomita
article en

Abstract

No abstract available for this paper.
HaiganVol. 65(7)
Kumamoto University Hospital (JP)
Good health and well-being
Openalex Percentile: Top 28%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

<i>MET</i> Exon 14 Skipping-positive Lung Cancer That Maintained a Complete Response After Pembrolizumab Discontinuation: a Case Report — Koichi Saruwatari, Shinji Iyama, et al. · Haigan (2025) | TGRS Research Map | TGRS